Literature DB >> 34141429

Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.

María Fernanda Ruiz1,2, María Verónica Gennaro1,3, Laura C Bastone4, Alicia R Godoy1, Mónica Torruella4, Germán R Perez4,5.   

Abstract

The present study aimed to evaluate the impact caused by the 2016 World Health Organization (WHO) diagnostic classification of gliomas in 139 patients studied in Argentina. Formalin-fixed paraffin-embedded tissues were used for histological and immunohistochemical analysis [glial fibrillary acidic protein, KI67, synaptophysin and isocitrate dehydrogenase (IDH)1-R132H]. DNA from formalin-fixed paraffin-embedded tissues was used for molecular analysis: 1p/19q co-deletion and mutation status of the IDH gene. These experiments were performed by direct Sanger sequencing and multiplex ligation-dependent probe amplification. According to the new classification, diagnoses included oligodendroglioma IDH-mutant and 1p/19q co-deletion (4.20%), anaplastic oligodendroglioma IDH-mutant and 1p/19q co-deletion (2.52%), diffuse astrocytoma IDH-mutant (6.72%), diffuse astrocytoma IDH-wild type (1.68%), anaplastic astrocytoma IDH-mutant (5.04%), anaplastic astrocytoma IDH-wild type (8.40%), glioblastoma IDH-mutant (5.88%) and glioblastoma IDH-wild type (65.56%). Regarding tumor histology, 60% of oligodendrogliomas, 35% of astrocytoma and 100% of unclassified gliomas were re-classified, while glioblastomas maintained their initial classification. Additionally, the present study evaluated the prognostic value of the histological grade for the 2007 and 2016 WHO classifications of gliomas. The histological subgroup associated with longer overall survival (OS) was grade II glioma (OS-2007WHO, 35.6 months; and OS-2016WHO, 47.7 months). Glioblastoma was the subgroup associated with a poor outcome (OS-2007WHO, 10.4 months; and OS-2016WHO, 11.1 months). The present study evaluated the OS of tumor grade subgroups with respect to their IDH status. For all subgroups, IDH-mutant tumors were associated with an improved prognosis compared with IDH-wild type tumors. The results suggested that the incorporation of molecular biomarkers in the new WHO classification improves tumor characterization and prognostic value of the subgroups.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  astrocytoma; diffuse glioma; glioblastoma; molecular classification; oligodendroglioma

Year:  2021        PMID: 34141429      PMCID: PMC8204142          DOI: 10.3892/mco.2021.2312

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  35 in total

1.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.

Authors:  Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-08-21       Impact factor: 17.088

2.  Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA.

Authors:  R I Skotheim; C B Diep; S M Kraggerud; K S Jakobsen; R A Lothe
Journal:  Cancer Genet Cytogenet       Date:  2001-05

3.  Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.

Authors:  Maarten M J Wijnenga; Hendrikus J Dubbink; Pim J French; Nathalie E Synhaeve; Winand N M Dinjens; Peggy N Atmodimedjo; Johan M Kros; Clemens M F Dirven; Arnaud J P E Vincent; Martin J van den Bent
Journal:  Acta Neuropathol       Date:  2017-10-19       Impact factor: 17.088

4.  cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Authors:  David N Louis; Pieter Wesseling; Werner Paulus; Caterina Giannini; Tracy T Batchelor; J Gregory Cairncross; David Capper; Dominique Figarella-Branger; M Beatriz Lopes; Wolfgang Wick; Martin van den Bent
Journal:  Acta Neuropathol       Date:  2018-01-25       Impact factor: 17.088

5.  Histology of the central nervous system.

Authors:  Robert H Garman
Journal:  Toxicol Pathol       Date:  2010-11-30       Impact factor: 1.902

6.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

7.  cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Eric C Holland; David N Louis; Robert B Jenkins; B K Kleinschmidt-DeMasters; Arie Perry; Guido Reifenberger; Roger Stupp; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2018-09-26       Impact factor: 17.088

8.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

9.  Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation.

Authors:  George S Stoyanov; Deyan L Dzhenkov; Martina Kitanova; Ivan S Donev; Peter Ghenev
Journal:  Cureus       Date:  2017-06-26

10.  International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading.

Authors:  David N Louis; Arie Perry; Peter Burger; David W Ellison; Guido Reifenberger; Andreas von Deimling; Kenneth Aldape; Daniel Brat; V Peter Collins; Charles Eberhart; Dominique Figarella-Branger; Gregory N Fuller; Felice Giangaspero; Caterina Giannini; Cynthia Hawkins; Paul Kleihues; Andrey Korshunov; Johan M Kros; M Beatriz Lopes; Ho-Keung Ng; Hiroko Ohgaki; Werner Paulus; Torsten Pietsch; Marc Rosenblum; Elisabeth Rushing; Figen Soylemezoglu; Otmar Wiestler; Pieter Wesseling
Journal:  Brain Pathol       Date:  2014-09-10       Impact factor: 6.508

View more
  2 in total

1.  Trophinin-associated protein expression correlates with shorter survival of patients with glioma: a study based on multiple data fusion analysis.

Authors:  Yong Sun; Zhen Dong Liu; Run Ze Liu; Xiao Yu Lian; Xing Bo Cheng; Yu Long Jia; Bin Feng Liu; Yan Zheng Gao; Xinjun Wang
Journal:  Mol Biol Rep       Date:  2022-06-16       Impact factor: 2.742

2.  Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models.

Authors:  Georgina A Cardama; Julian Maggio; Lucas Valdez Capuccino; Nazareno Gonzalez; Valentina Matiller; Hugo H Ortega; German R Perez; Ignacio A Demarco; Eduardo Spitzer; Daniel E Gomez; Pablo Lorenzano Menna; Daniel F Alonso
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.